COMP <GO>
CBT vs LIN // EV/EBITDA & P/E VALUATION
Cabot Corporation (NYSE) VS. Linde plc (NASDAQ) • 15-METRIC TALLY: CBT 5
— LIN 5
▲ EV/EBITDA & P/E VALUATION LEADER: CBT
LAST: $73.85 (+0.11%) • MKT CAP: $3.81B
valuation
5.2x
LAST: $503.15 (-0.99%) • MKT CAP: $231.94B
valuation
18.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CBT VS. LIN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CBT | LIN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 25.30% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 22.30% | 13.10% | +9.20 | CBT | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 5.2x | 18.5x | -13.30 | CBT | /valuation <GO> |
| Free Cash Flow Yield | 10.25% | 2.19% | +8.06 | CBT | /fcf-yield <GO> |
| Operating Margin | 16.70% | 26.30% | -9.60 | LIN | /operating-margins <GO> |
| Net Profit Margin | 8.90% | 20.30% | -11.40 | LIN | /net-margins <GO> |
| Revenue Growth (YoY) | -7.00% | 3.00% | -10.00 | LIN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.52% | 1.21% | +1.31 | CBT | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 3.93 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.4 | 56.6 | -13.24 | LIN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.01 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.7x | 31.2x | -20.50 | CBT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.81B | $231.94B | -$228.13B | LIN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CBT REV | LIN REV | CBT GROSS % | LIN GROSS % | CBT FCF | LIN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.71B | $33.99B | 25.3% | — | $391.0M | $5.09B |
| FY 2024 | $3.99B | $33.01B | 24.0% | — | $451.0M | $4.93B |
| FY 2023 | $3.93B | $32.85B | — | — | $595.0M | $7.83B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CBT // BETA —
LIN // BETA 1.01